Environmentally benign first derivative synchronous spectrofluorimetry for the analysis of two binary mixtures containing duloxetine with avanafil or tadalafil in spiked plasma samples

• Published in: Luminescence (Chichester, England) Vol. 39; no. 3; pp. e4696 - n/a
• Main Authors: Abd‐AlGhafar, Walaa Nabil, Abo Shabana, Rasha, El‐Shaheny, Rania, Tolba, Manar M.
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.03.2024
• Subjects: Antidepressants; avanafil; Binary mixtures; Blood plasma; derivative synchronous spectrofluorimetry; Duloxetine; Duloxetine Hydrochloride; Ethanol; Fluids; human plasma; Humans; Pharmaceutical Preparations; Pharmacokinetics; Pyrimidines; Quality control; Sexual behavior; Side effects; Spectrofluorimetry; Spectrometry, Fluorescence - methods; Tadalafil; Wavelength; avanafil; duloxetine; tadalafil; derivative synchronous spectrofluorimetry; human plasma
• ISSN: 1522-7235; 1522-7243
• DOI: 10.1002/bio.4696

Antidepressants can cause sexual dysfunction side effects, necessitating the co‐administration of phosphodiesterase type 5 inhibitors. The simultaneous determination of these drugs in biological fluids is critical for therapeutic drug monitoring. For the first time, two binary mixtures containing duloxetine with either avanafil or tadalafil were estimated utilizing simple green spectrofluorimetric methods without the need for a previous separation step. The study was based on first derivative synchronous spectrofluorimetry in ethanol using a change in wavelength difference (∆λ) of 20 and 25 nm for the first and second combinations, respectively. Duloxetine and avanafil were estimated at 297.7 and 331 nm in their binary mixture, while duloxetine and tadalafil were determined at 290.3 and 297.7 nm, respectively. The linearity was achieved over the ranges of 0.1–1.5 μg mL−1 for both duloxetine and avanafil and 0.01–0.40 μg mL−1 for tadalafil, with limits of detection of 0.013, 0.022, and 0.004 μg mL−1 for duloxetine, avanafil, and tadalafil, respectively. Successful application of the developed approaches was accomplished for the estimation of the two mixtures in dosage forms as well as human plasma with excellent percentage recoveries (96–103.75% in plasma), which supports their suitability for use in quality control laboratories and pharmacokinetic studies. Moreover, the adopted approaches' greenness was evidenced by applying three tools. First derivative synchronous spectrofluorimetric analysis of two binary mixtures containing duloxetine with either avanafil or tadalafil. Application to pharmaceutical dosage forms and human plasma is achieved with excellent recoveries. Eco‐friendly approaches using ethanol as a green solvent and an assessment of the greenness of the methods are carried out.